Investing News Coverage

LexaGene CEO Dr. Jack Regan talks with Investing news about post-raise plans for commercialization. In the article, he states, “The technical risk is well behind us, and now it’s really more of a manufacturing exercise and getting it right so that the user experience is everything we believe it can be,” he said. “(We believe) it’s going to be something which is robust and well-liked by all of the users.” Read story.